Grifols SA (GIFLF)
12.72
0.00 (0.00%)
USD |
OTCM |
Nov 17, 16:00
Grifols Enterprise Value : 21.39B for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 21.39B |
| November 16, 2026 | 21.39B |
| November 13, 2026 | 21.39B |
| November 12, 2026 | 21.39B |
| November 11, 2026 | 21.39B |
| November 10, 2026 | 21.39B |
| November 09, 2026 | 21.39B |
| November 06, 2026 | 21.39B |
| November 05, 2026 | 21.39B |
| November 04, 2026 | 21.06B |
| November 03, 2026 | 21.06B |
| November 02, 2026 | 21.06B |
| October 30, 2026 | 19.91B |
| October 29, 2026 | 19.91B |
| October 28, 2026 | 19.91B |
| October 27, 2026 | 19.91B |
| October 26, 2026 | 19.91B |
| October 23, 2026 | 19.91B |
| October 22, 2026 | 19.91B |
| October 21, 2026 | 19.91B |
| October 20, 2026 | 19.91B |
| October 19, 2026 | 19.91B |
| October 16, 2026 | 19.91B |
| October 15, 2026 | 19.91B |
| October 14, 2026 | 19.91B |
| Date | Value |
|---|---|
| October 13, 2026 | 19.91B |
| October 12, 2026 | 20.31B |
| October 09, 2026 | 20.31B |
| October 08, 2026 | 20.31B |
| October 07, 2026 | 20.31B |
| October 06, 2026 | 20.31B |
| October 05, 2026 | 20.31B |
| October 02, 2026 | 20.31B |
| October 01, 2026 | 20.31B |
| September 30, 2026 | 20.31B |
| September 29, 2026 | 19.51B |
| September 28, 2026 | 19.51B |
| September 25, 2026 | 19.51B |
| September 24, 2026 | 19.51B |
| September 23, 2026 | 19.51B |
| September 22, 2026 | 19.51B |
| September 21, 2026 | 19.51B |
| September 18, 2026 | 19.51B |
| September 17, 2026 | 19.51B |
| September 16, 2026 | 19.51B |
| September 15, 2026 | 19.51B |
| September 14, 2026 | 19.64B |
| September 11, 2026 | 19.64B |
| September 10, 2026 | 19.64B |
| September 09, 2026 | 19.47B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Pharma Mar SA | 1.137B |
| Oryzon Genomics SA | 215.46M |
| Agenus, Inc. | 464.42M |
| Amgen, Inc. | 288.51B |
| Anika Therapeutics, Inc. | 153.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 208.24M |
| Revenue (Quarterly) | 2.347B |
| Total Expenses (Quarterly) | 2.161B |
| EPS Diluted (Quarterly) | 0.2739 |
| Gross Profit Margin (Quarterly) | 39.56% |
| Profit Margin (Quarterly) | 8.87% |
| Earnings Yield | 6.53% |
| Operating Earnings Yield | 16.71% |
| Normalized Earnings Yield | 6.529 |